Group 1 - The core point of the news is that Jingtai Holdings (2228.HK) experienced a significant stock price increase of nearly 23%, reaching a new high of 8.1 HKD since February 25, following the announcement of a major collaboration with DoveTree [1] - Jingtai Technology announced on August 5 that it has completed a pipeline cooperation agreement with DoveTree, with a total order scale of approximately 470 billion HKD (59.9 billion USD) [1][3] - The agreement includes an initial payment of approximately 4 billion HKD (510 million USD) and potential further payments of about 3.85 billion HKD (490 million USD), along with milestone payments and sales shares amounting to approximately 462 billion HKD (58.9 billion USD) [3] Group 2 - The collaboration involves multiple preclinical stage large and small molecule innovative drug assets, with Jingtai Technology having the right to develop new drugs targeting specific DoveTree-designated targets [3] - DoveTree retains exclusive global development and commercialization rights for the related drugs [3] - This partnership sets a new record for order scale in the field of AI and robotics in new drug development [3]
签下470亿港元创记录订单，并已收到协议约定的首付款约4亿港元！晶泰控股飙升近23%，股价创2月25日以来新高
Ge Long Hui·2025-08-06 01:56